Impact of Germline Genetic Testing for Men with Prostate Cancer on Active Surveillance
Abstract
Active surveillance (AS) is now the standard-of-care treatment for men with low-risk prostate cancer. Although there is an association between the presence of germline pathogenic variants in certain DNA-damage repair genes and aggressive prostate cancer, whether presence of these mutations also lead to worse clinical outcomes in men on AS has not been systematically studied. We will conduct a prospective, single-arm clinical trial to examine how germline genetic testing affects men with prostate cancer on AS, both in terms of psychological outcomes and impact on clinical decision-making. We will also study the prevalence of germline pathogenic or likely pathogenic variants in DDR genes in this population and compare pathologic outcomes between germline DDR mutation carriers vs non-carriers. We will recruit 600 participants over 3 years. The specific aims include: (1): to describe the prevalence of pathogenic and likely pathogenic germline variants in DNA damage repair genes in patients with prostate cancer on active surveillance and to identify risk factors for P/LP variant carriers; (2)to compare pathologic outcomes in patients with germline variants versus those without;and (3) to evaluate the acceptability and psychological outcomes of genetic testing in menwith prostate cancer on active surveillance, and to compare psychological outcomes andclinical decision-making between those with and those without P/LP germline DDR variants.
Document Details
- Document Type
- Technical Report
- Publication Date
- May 01, 2021
- Accession Number
- AD1143207
Entities
People
- Maria I Carlo
Organizations
- Memorial Sloan Kettering Cancer Center